RecruitingPhase 3NCT06935357
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biogen
- Principal Investigator
- Medical DirectorBiogen
- Intervention
- Felzartamab(drug)
- Enrollment
- 454 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Applied Research Center of Arkansas, Little Rock, Arkansas, United States
- Kidney & Hypertension Center - Apple Valley, Apple Valley, California, United States
- Scripps Green Hospital, Carlsbad, California, United States
- National Institute of clinical Research Administration Office, Garden Grove, California, United States
- FOMAT Medical Research - FOMAT - PPDS, Oxnard, California, United States
- North America Research Institute-San Dimas, San Dimas, California, United States
- Nova Clinical Research, LLC, Bradenton, Florida, United States
- Royal Research, Corp., Hollywood, Florida, United States
- Central Florida Kidney Specialists, Orlando, Florida, United States
- CDC Research Institute, LLC, Port Saint Lucie, Florida, United States
- American Clinical Trials LLC, Acworth, Georgia, United States
- The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Human Immunology Biosciences, Inc. (HI-Bio)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06935357 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital